ARTICLE SUMMARY:
Coming out of last year, all of the signs pointed to a robust first quarter with continued strong M&A and a resurgence in IPOs. The results defied expectations: a decline in M&A valuation, no IPOs and a drop in follow-on offerings. Yet, the macro environment remains strong, providing a cause for optimism for the rest of 2018.
Entering the first quarter of this year, all the signs pointed to a robust US medtech climate.
